Literature DB >> 31086260

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.

Kerry A Rogers1, Luay Mousa1, Qiuhong Zhao1, Seema A Bhat1, John C Byrd1, Zeinab El Boghdadly2, Tomas Guerrero3, Lauren B Levine4, Fabienne Lucas1, Polina Shindiapina1, Audrey M Sigmund1, Matthew Sullivan3, Tracy E Wiczer4, Jennifer A Woyach5, Farrukh T Awan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31086260      PMCID： PMC7425823          DOI： 10.1038/s41375-019-0481-1

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.

Authors:  Marco Tuccori; Daniele Focosi; Corrado Blandizzi; Matteo Pelosini; Sabrina Montagnani; Fabrizio Maggi; Mauro Pistello; Luca Antonioli; Matteo Fornai; Pasquale Pepe; Giuseppe Rossi; Mario Petrini
Journal:  Oncologist       Date:  2010-11-01

2.  Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Lindsey Robert Baden; Sankar Swaminathan; Michael Angarone; Gayle Blouin; Bernard C Camins; Corey Casper; Brenda Cooper; Erik R Dubberke; Ashley Morris Engemann; Alison G Freifeld; John N Greene; James I Ito; Daniel R Kaul; Mark E Lustberg; Jose G Montoya; Ken Rolston; Gowri Satyanarayana; Brahm Segal; Susan K Seo; Shmuel Shoham; Randy Taplitz; Jeffrey Topal; John W Wilson; Karin G Hoffmann; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2016-07       Impact factor: 11.908

3.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

4.  Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Authors:  David Ghez; Anne Calleja; Caroline Protin; Marine Baron; Marie-Pierre Ledoux; Gandhi Damaj; Mathieu Dupont; Brigitte Dreyfus; Emmanuelle Ferrant; Charles Herbaux; Kamel Laribi; Ronan Le Calloch; Marion Malphettes; Franciane Paul; Laetitia Souchet; Malgorzata Truchan-Graczyk; Karen Delavigne; Caroline Dartigeas; Loïc Ysebaert
Journal:  Blood       Date:  2018-02-01       Impact factor: 22.113

5.  Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.

Authors:  Inhye E Ahn; Theresa Jerussi; Mohammed Farooqui; Xin Tian; Adrian Wiestner; Juan Gea-Banacloche
Journal:  Blood       Date:  2016-08-08       Impact factor: 22.113

6.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

7.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

8.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis.

Authors:  Amelia Bercusson; Thomas Colley; Anand Shah; Adilia Warris; Darius Armstrong-James
Journal:  Blood       Date:  2018-07-18       Impact factor: 25.476

Review 10.  Control of Phagocytosis by Microbial Pathogens.

Authors:  Eileen Uribe-Querol; Carlos Rosales
Journal:  Front Immunol       Date:  2017-10-24       Impact factor: 7.561
View more
  21 in total

Review 1.  Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Authors:  Danielle Wallace; Patrick M Reagan
Journal:  Drugs       Date:  2021-03-30       Impact factor: 9.546

Review 2.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

3.  Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.

Authors:  Christine E Ryan; Matthew P Cheng; Nicolas C Issa; Jennifer R Brown; Matthew S Davids
Journal:  Blood Adv       Date:  2020-04-14

4.  Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.

Authors:  Martin Wist; Laura Meier; Orit Gutman; Jennifer Haas; Sascha Endres; Yuan Zhou; Reinhild Rösler; Sebastian Wiese; Stephan Stilgenbauer; Elias Hobeika; Yoav I Henis; Peter Gierschik; Claudia Walliser
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

5.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

6.  Invasive Aspergillosis in Patients Treated With Ibrutinib.

Authors:  Moritz Fürstenau; Florian Simon; Oliver A Cornely; Tillman Hicketier; Barbara Eichhorst; Michael Hallek; Sibylle C Mellinghoff
Journal:  Hemasphere       Date:  2020-02-13

Review 7.  BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.

Authors:  Marzia Palma; Tom A Mulder; Anders Österborg
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

Review 8.  Targeting Bruton's Tyrosine Kinase in CLL.

Authors:  Inhye E Ahn; Jennifer R Brown
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

Review 9.  Infections associated with the new 'nibs and mabs' and cellular therapies.

Authors:  Marcela V Maus; Michail S Lionakis
Journal:  Curr Opin Infect Dis       Date:  2020-08       Impact factor: 4.968

Review 10.  New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies.

Authors:  Corrado Girmenia
Journal:  F1000Res       Date:  2019-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.